| DLL4 | Delta-like-ligand 4 |
| VEGF | Vascular Endothelial Growth Factor |
| VEGFR | Vascular Endothelial Growth Factor Receptor |
| FDA | Food and Drug Administration |
| PDX | Patient-Derived Xenograft |
| CSC | Cancer stem cell |
| scFv | Single-chain Fv |
| IV | Intravenous |
| MTD | Maximum Tolerated Dose |
| DLT | Dose-limiting Toxicity |
| AEs | Adverse Events |
| SD | Stable Disease |
| PR | Partial Response |
| %TGI | % Tumor Growth Inhibition |
| IACUC | Institutional Animal Care and Use Committee |
| HCC | Hepatocellular Carcinoma |
| NSCLC | Non-Small Cell Lung Cancer |